# Safety Study of Anti-IgE Immunotherapy in Allergic Patients

> **NCT00439621** · PHASE2 · COMPLETED · sponsor: **Resistentia Pharmaceuticals AB** · enrollment: 42 (actual)

## Conditions studied

- Allergy

## Interventions

- **BIOLOGICAL:** RP 01

## Key facts

- **NCT ID:** NCT00439621
- **Lead sponsor:** Resistentia Pharmaceuticals AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-08
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2008-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439621, "Safety Study of Anti-IgE Immunotherapy in Allergic Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00439621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*